Squarepoint Ops LLC Grows Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Squarepoint Ops LLC grew its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 105.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 211,842 shares of the company's stock after purchasing an additional 108,719 shares during the quarter. Squarepoint Ops LLC owned 0.10% of Taysha Gene Therapies worth $366,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Ground Swell Capital LLC acquired a new stake in Taysha Gene Therapies during the 4th quarter worth approximately $25,000. Cibc World Markets Corp purchased a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $28,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at $31,000. Hsbc Holdings PLC boosted its holdings in Taysha Gene Therapies by 65.6% in the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares during the period. Finally, AXQ Capital LP purchased a new position in Taysha Gene Therapies in the fourth quarter valued at $39,000. Institutional investors and hedge funds own 77.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Chardan Capital upped their target price on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. JMP Securities lifted their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a research note on Thursday, May 29th. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective (up from $6.00) on shares of Taysha Gene Therapies in a research report on Monday, June 2nd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of "Buy" and an average target price of $7.57.

Insider Buying and Selling at Taysha Gene Therapies

In other news, major shareholder Paul B. Manning bought 750,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, May 30th. The stock was acquired at an average cost of $2.75 per share, with a total value of $2,062,500.00. Following the acquisition, the insider now owns 2,841,704 shares of the company's stock, valued at approximately $7,814,686. This trade represents a 35.86% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 2.70% of the stock is currently owned by insiders.

Taysha Gene Therapies Stock Down 1.4%

Taysha Gene Therapies stock traded down $0.04 during mid-day trading on Monday, hitting $2.80. The company had a trading volume of 1,889,982 shares, compared to its average volume of 3,040,899. The stock has a market cap of $601.05 million, a price-to-earnings ratio of 4.44 and a beta of 1.04. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $4.32. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average of $2.04 and a 200 day moving average of $1.92.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. During the same quarter in the prior year, the business posted ($0.10) EPS. On average, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.